


# VMS GREATLY IMPACT QUALITY OF LIFE

The burden of vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot flashes and night sweats



**UP TO 80% OF WOMEN WILL BE AFFECTED BY VMS,** the most commonly reported and most bothersome symptoms related to menopause.<sup>1-5</sup>

A growing number of women can expect VMS to diminish their quality of life for years to come.<sup>2,5</sup>

Women experience VMS for a median duration of

## 7.4 YEARS

However, some women may experience symptoms for 10 or more years.<sup>2,3,5</sup>

### WOMEN LIVING WITH MENOPAUSE-RELATED SYMPTOMS REPORTED THE FOLLOWING SEVERE IMPACTS ON THEIR QUALITY OF LIFE:<sup>W</sup>



**72% feeling tired/  
worn out<sup>†</sup>**

**67% lack of  
energy<sup>†</sup>**



**62% hot flashes<sup>‡</sup>**



**57% sleep  
disturbances<sup>‡</sup>**

**55% night  
sweats<sup>‡</sup>**



**50% work  
disruptions<sup>‡</sup>**

It's estimated that  
10% of women will  
leave the workforce<sup>‡</sup>



**41% negative  
effect on  
relationships with  
spouse or partner<sup>‡</sup>**

**37% low libido<sup>‡</sup>**



**39% negative  
effect on mood<sup>‡</sup>**

## VMS ARE WORTH DISCUSSING WITH YOUR MENOPAUSAL PATIENTS

<sup>†</sup> Results from a multinational study (Brazil, Canada, Mexico and 4 Nordic European countries) including prevalence results of moderate to severe VMS (N=12,268 postmenopausal women) and secondary analysis of how VMS affect quality of life (N=2176 perimenopausal and postmenopausal women).<sup>4</sup>

<sup>‡</sup> Survey results of 1023 Canadian women aged 40-60.<sup>5,6</sup>

**References:** **1.** Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. *Menopause Practice: A Clinician's Guide*. 6<sup>th</sup> ed. Pepper Pike, OH: The North American Menopause Society, 2019;43-55. **2.** Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern Med*. 2015;175(4):531-9. **3.** Yuksel N, Evaniuk D, Huang L, et al. Guideline No. 422a: Menopause: vasomotor symptoms, prescription therapeutic agents, complementary and alternative medicine, nutrition, and lifestyle. *J Obstet Gynaecol Can*. 2021 Oct;43(10):1188-1204.e1. **4.** Menopause Foundation of Canada. The Silence and the Stigma: Menopause in Canada. 2022; 1-21. Accessed February 7, 2024. [https://menopausefoundationcanada.ca/wp-content/uploads/2023/01/MFC\\_The-Silence-and-the-Stigma\\_Menopause-in-Canada\\_Oct22\\_v2.pdf](https://menopausefoundationcanada.ca/wp-content/uploads/2023/01/MFC_The-Silence-and-the-Stigma_Menopause-in-Canada_Oct22_v2.pdf) **5.** Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause - global prevalence, physiology and implications. *Nat Rev Endocrinol*. 2018;14(4):199-215. **6.** Todorova L, Bonassi R, Guerrero C, et al. Prevalence and impact of vasomotor symptoms due to menopause among women in Brazil, Canada, Mexico, and Nordic Europe: a cross-sectional survey. *Menopause*. 2023;30(12):1179-1189. **7.** Menopause Foundation of Canada. Menopause and Work in Canada. Accessed February 7, 2024. [https://menopausefoundationcanada.ca/pdf\\_files/Menopause\\_Work\\_Canada\\_2023EN.pdf](https://menopausefoundationcanada.ca/pdf_files/Menopause_Work_Canada_2023EN.pdf)



©2024 Astellas Pharma Canada, Inc. All rights reserved.  
Astellas and the flying star logo are trademarks of Astellas Pharma Inc.  
MAT-CA-NON-2024-00097 03/24